UroGen Pharma (NASDAQ:URGN) Coverage Initiated at Scotiabank

Scotiabank initiated coverage on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a research report sent to investors on Wednesday, Marketbeat.com reports. The firm issued a sector outperform rating and a $23.00 price objective on the stock.

A number of other analysts have also recently commented on the stock. LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price objective for the company. D. Boral Capital restated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Monday, March 10th. Finally, HC Wainwright lowered their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, UroGen Pharma presently has an average rating of "Buy" and an average target price of $32.86.

UroGen Pharma Price Performance

Shares of UroGen Pharma stock traded down $0.72 during trading on Wednesday, reaching $9.67. The company's stock had a trading volume of 741,549 shares, compared to its average volume of 511,147. The stock has a 50-day moving average price of $10.49 and a two-hundred day moving average price of $11.19. The stock has a market capitalization of $445.73 million, a P/E ratio of -3.07 and a beta of 0.80. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma has a one year low of $8.94 and a one year high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analysts' expectations of $25.25 million. As a group, sell-side analysts anticipate that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Insider Transactions at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company's stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares of the company's stock, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of UroGen Pharma

Several large investors have recently modified their holdings of URGN. RTW Investments LP increased its holdings in UroGen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock valued at $40,841,000 after buying an additional 47,447 shares during the period. Toronto Dominion Bank bought a new stake in UroGen Pharma during the fourth quarter worth $18,628,000. Vestal Point Capital LP boosted its holdings in shares of UroGen Pharma by 307.5% in the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock valued at $17,360,000 after purchasing an additional 1,230,000 shares in the last quarter. Acorn Capital Advisors LLC acquired a new position in shares of UroGen Pharma during the 4th quarter worth $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in UroGen Pharma by 2.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company's stock valued at $14,667,000 after acquiring an additional 36,084 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.